You are here: Welcome to the MPKB » Welcome to the MPKB » Autoimmunity Research Foundation » Timeline of the Marshall Protocol Discoveries
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
home:arf:timeline [02.14.2019] – [Notes and comments] sallieqhome:arf:timeline [09.14.2022] (current) – external edit 127.0.0.1
Line 5: Line 5:
 **1974** – Teaching in Papua New Guinea, Trevor Marshall experiences tropical sun - an experience which would prove crucial twelve years later. **1974** – Teaching in Papua New Guinea, Trevor Marshall experiences tropical sun - an experience which would prove crucial twelve years later.
  
-**1978-1982** – Marshall works towards his PhD thesis. His work includes the design of portable, battery operated programmable pumps for the delivery of pulsatile GnRH and LHRH for treating cryptorchidism as well as both male and female infertility.(({{pubmed>long:6135766}})) (({{pubmed>long:6428734}})) The use of pulsed doses of therapeutic drugs has a key place in the Marshall Protocol years later.+**1978-1982** – Marshall works towards his PhD thesis. His work includes the design of portable, battery operated programmable pumps for the delivery of pulsatile GnRH and LHRH for treating cryptorchidism as well as both male and female infertility.(({{pmid>long:6135766}})) (({{pmid>long:6428734}})) The use of pulsed doses of therapeutic drugs has a key place in the Marshall Protocol years later.
  
 **1981** – While a Visiting Scientist in the Dept. of Surgery at Toronto's Hospital for Sick Children, Marshall sees IBM's presentation of a few nano-seconds of life of a humulin molecule (synthetic human insulin). The presentation is one of the first //in silico// models. **1981** – While a Visiting Scientist in the Dept. of Surgery at Toronto's Hospital for Sick Children, Marshall sees IBM's presentation of a few nano-seconds of life of a humulin molecule (synthetic human insulin). The presentation is one of the first //in silico// models.
Line 17: Line 17:
 **1999** – Marshall learns that other patients with sarcoidosis who were administered Angiotensin Receptor Blockers (ARBs) often developed a neurological reaction. Marshall starts a sabbatical in early 2001 in order to further investigate this reaction. **1999** – Marshall learns that other patients with sarcoidosis who were administered Angiotensin Receptor Blockers (ARBs) often developed a neurological reaction. Marshall starts a sabbatical in early 2001 in order to further investigate this reaction.
  
-**2001** - Marshall submits paper explaining that sarcoidosis could have a bacterial pathogenesis. Three revisions of the paper are rejected by the journal "Sarcoidosis, Vasculitis and Diffuse Lung Diseases"  as having no potential interest for its readers. +**2001** - Marshall submits paper explaining that sarcoidosis could have a bacterial pathogenesis. Three revisions of the paper are rejected by the journal //Sarcoidosis, Vasculitis and Diffuse Lung Diseases//  as having no potential interest for its readers. 
  
 **2001 March** - The first early adopter, Elaine Emmi, begins the use of an ARB to treat her sarcoidosis. **2001 March** - The first early adopter, Elaine Emmi, begins the use of an ARB to treat her sarcoidosis.
  
-**2001 December** - Nilsson //et al.// publish article in //Journal of infectious disease// showing that deceased sarcoidosis patients contain the genetic material from //Rickettsia helvetica// in the cytoplasm of cells within sarcoid granuloma.(({{pubmed>long:11930323}})) Marshall commences using pulsed, sub-inhibitory, doses of antibiotics in an attempt to reverse his sarcoidosis.+**2001 December** - Nilsson //et al.// publish article in //Journal of infectious disease// showing that deceased sarcoidosis patients contain the genetic material from //Rickettsia helvetica// in the cytoplasm of cells within sarcoid granuloma.(({{pmid>long:11930323}})) Marshall commences using pulsed, sub-inhibitory, doses of antibiotics in an attempt to reverse his sarcoidosis.
  
-**2002 March** –  Marshall registers [[http://sarcinfo.com|Sarcinfo.com]], a forum-based website where patients sick with sarcoidosis begin to discuss a novel antibacterial therapy for the disease.+**2002 March** –  Marshall registers "//Sarcinfo.com//", a forum-based website where patients sick with sarcoidosis begin to discuss a novel antibacterial therapy for the disease.
  
 **2002 May** –  Marshall changes to using the ARB olmesartan medoxomil (Benicar).  **2002 May** –  Marshall changes to using the ARB olmesartan medoxomil (Benicar). 
  
-**2002 August** – Trevor Marshall and Frances (Liz) Marshall publish NetPrint, "[[http://clinmed.netprints.org/cgi/content/full/2002080006|Valsartan Dosing Regime Modulates Psychotic Events in Two Sarcoidosis Patients]]." The case report shares early observations that valsartan (Diovan) induced hallucinations and psychedelic dreams. Convinced that they have developed a pathogenic description of sarcoidosis, they write the Netprint "[[http://clinmed.netprints.org/cgi/content/full/2002080004|Remission in Sarcoidosis]]"+**2002 August** – Trevor Marshall and Frances (Liz) Marshall publish NetPrint, "//Valsartan Dosing Regime Modulates Psychotic Events in Two Sarcoidosis Patients//". The case report shares early observations that valsartan (Diovan) induced hallucinations and psychedelic dreams. Convinced that they have developed a pathogenic description of sarcoidosis, they write the Netprint "//Remission in Sarcoidosis//"
  
-**2002 September** – "[[http://clinmed.netprints.org/cgi/content/full/2002080004|Remission in Sarcoidosis]]" is published (in summary) at Mercola.com. Later that month, early adopter (and colleague) Belinda Fenter commences pulsed minocycline.+**2002 September** –  //Remission in Sarcoidosis// is published (in summary) at Mercola.com. Later that month, early adopter (and colleague) Belinda Fenter commences pulsed minocycline.
  
 **2002 December** – Early adopter (and colleague) Meg Mangin commences pulsed tetracycline.  **2002 December** – Early adopter (and colleague) Meg Mangin commences pulsed tetracycline. 
  
  
-**2003 January** – A meeting with Dr. Alan Cantwell brought to light papers by Lida Mattman.(({{pubmed>long:8711683}})) (({{pubmed>long:4111724}})) (({{pubmed>long:4100503}})) +**2003 January** – A meeting with Dr. Alan Cantwell brought to light papers by Lida Mattman.(({{pmid>long:8711683}})) (({{pmid>long:4111724}})) (({{pmid>long:4100503}})) 
- Seperately, images from Emil Wirostko's group(({{pubmed>long:15043554}})) (({{pubmed>long:8622416}})) (({{pubmed>long:7892050}})) finally confirmed that a cytoplasmic microbiota of intraphagocytic, L-form bacteria must drive the biochemical changes observed in sarcoidosis.+ Seperately, images from Emil Wirostko's group(({{pmid>long:15043554}})) (({{pmid>long:8622416}})) (({{pmid>long:7892050}})) finally confirmed that a cytoplasmic microbiota of intraphagocytic, L-form bacteria must drive the biochemical changes observed in sarcoidosis.
  
-**2003 January** – Mangin changes to minocycline and commences concurrent olmesartan. Fenter also commences using olmesartan. They are joined by Ms. Dale Thurlow, and Marshall's Protocol has taken root. Later that month Trevor Marshall and Frances (Liz) Marshall publish "[[http://clinmed.netprints.org/cgi/content/full/2003010001|New Treatments Emerge as Sarcoidosis Yields Up its Secrets]]" on Clinmed, after it is savaged by two pulmonologist peer-reviewers for "BMC Pulmonary Medicine"+**2003 January** – Mangin changes to minocycline and commences concurrent olmesartan. Fenter also commences using olmesartan. They are joined by Ms. Dale Thurlow, and Marshall's Protocol has taken root. Later that month Trevor Marshall and Frances (Liz) Marshall publish "New Treatments Emerge as Sarcoidosis Yields Up its Secrets" on Clinmed, after it is savaged by two pulmonologist peer-reviewers for "BMC Pulmonary Medicine"
  
 **2004 April** – Autoimmunity Research Foundation is founded. **2004 April** – Autoimmunity Research Foundation is founded.
  
-**2004 June** – Trevor Marshall and Frances (Liz) Marshall publish "[[home:publications:marshall_autoimmunity_reviews_2003|Sarcoidosis succumbs to antibiotics: implications for autoimmune disease]]."(({{pubmed>long:15246025}})) This time it is accepted and published online in the peer-reviewed journal //Autoimmunity Reviews//, later to appear in the Print Edition. The paper explains how cell wall deficient bacteria are responsible for sarcoidosis and may in fact be responsible for all chronic diseases. It also describes a Jarisch-Herxheimer reaction resulting from endotoxin release as the microbes are killed.+**2004 June** – Trevor Marshall and Frances (Liz) Marshall publish "[[home:publications:marshall_autoimmunity_reviews_2003|Sarcoidosis succumbs to antibiotics: implications for autoimmune disease]]."(({{pmid>long:15246025}})) This time it is accepted and published online in the peer-reviewed journal //Autoimmunity Reviews//, later to appear in the Print Edition. The paper explains how cell wall deficient bacteria are responsible for sarcoidosis and may in fact be responsible for all chronic diseases. It also describes a Jarisch-Herxheimer reaction resulting from endotoxin release as the microbes are killed.
  
 **2004 July** – Marshall speaks at 4th International Congress on Autoimmunity in Budapest. **2004 July** – Marshall speaks at 4th International Congress on Autoimmunity in Budapest.
  
-**2004 July** – Marshall registers [[http://marshallprotocol.com|MarshallProtocol.com]], a website where patients sick with a range of chronic diseases discuss an antibacterial therapy since named the "Marshall Protocol." – Aussie Barb joins MarshallProtocol.com and begins to perform an invaluable behind-the-scenes role on the study site.+**2004 July** – Marshall registers [[https://marshallprotocol.com|MarshallProtocol.com]], a website where patients sick with a range of chronic diseases discuss an antibacterial therapy since named the "Marshall Protocol." – Aussie Barb joins MarshallProtocol.com and begins to perform an invaluable behind-the-scenes role on the study site.
  
-**2004 December** - The Journal of the Interregional Clinical-Diagnostic Center, Kazan, Russia, (ISSN: 1726-6149) publishes, in Russian translation, Marshall's paper "[[http://www.joimr.org/phorum/read.php?f=2&i=107&t=107|Antibacterial Therapy Induces Remission in Sarcoidosis]]" in its special issue on Sarcoidosis. +**2004 December** - [[https://www.joimr.org/|joimr]] The Journal of the Interregional Clinical-Diagnostic Center, Kazan, Russia, (ISSN: 1726-6149) publishes, in Russian translation, Marshall's paper "//Antibacterial Therapy Induces Remission in Sarcoidosis//" in its special issue on Sarcoidosis. 
  
 **2005 March ** – ARF's 'Recovering from Chronic Disease' conference held in Chicago. Notable speakers include Lida Mattman PhD and Dr. Andrew Wright. **2005 March ** – ARF's 'Recovering from Chronic Disease' conference held in Chicago. Notable speakers include Lida Mattman PhD and Dr. Andrew Wright.
  
-**2005 June** - Marshall publishes the English text of the Russian paper "[[http://www.joimr.org/phorum/read.php?f=2&i=107&t=107|Antibacterial Therapy Induces Remission in Sarcoidosis]]"+**2005 June** - Marshall publishes the English text of the Russian paper "//Antibacterial Therapy Induces Remission in Sarcoidosis//" [[https://www.joimr.org/|joimr]]
  
-**2005 July** – Marshall files for [[http://www.freepatentsonline.com/y2006/0025358.html|patent]] with US Patent and Trademark Office (eventually published in February 2006) which explains a method of killing the stealthy intracellular bacteria which cause many Th1 and "autoimmune" diseases. A [[http://www.freepatentsonline.com/y2007/0135504.html|second patent]] which specifies a broader range of chronic diseases is filed in December 2006.+**2005 July** – Marshall files for [[https://www.freepatentsonline.com/y2006/0025358.html|patent]] with US Patent and Trademark Office (eventually published in February 2006) which explains a method of killing the stealthy intracellular bacteria which cause many Th1 and "autoimmune" diseases. A [[https://www.freepatentsonline.com/y2007/0135504.html|second patent]] which specifies a broader range of chronic diseases is filed in December 2006.
  
-**2006 January** – Trevor Marshall, Robert Lee, and Frances (Liz) Marshall [[home:publications:marshall_theoretical_2006|publish paper]] in //Theoretical Biology & Medical Modelling// explaining how angiotensin receptor blockers directly modulate the immune system via the VDR, PPAR and CCR2b nuclear receptors.(({{pubmed>long:16403216}}))+**2006 January** – Trevor Marshall, Robert Lee, and Frances (Liz) Marshall [[home:publications:marshall_theoretical_2006|publish paper]] in //Theoretical Biology & Medical Modelling// explaining how angiotensin receptor blockers directly modulate the immune system via the VDR, PPAR and CCR2b nuclear receptors.(({{pmid>long:16403216}}))
  
 **2006 March** – As part of Visiting Professor Lecture Series, which is organized by the FDA's Center for Drug Evaluation and Research, Marshall presents on "[[home:publications:marshall_fda_cder_2006|Molecular genomics offers new insight into the exact mechanism of action of common drugs: ARBs, statins and corticosteroids]]." **2006 March** – As part of Visiting Professor Lecture Series, which is organized by the FDA's Center for Drug Evaluation and Research, Marshall presents on "[[home:publications:marshall_fda_cder_2006|Molecular genomics offers new insight into the exact mechanism of action of common drugs: ARBs, statins and corticosteroids]]."
Line 63: Line 63:
 **2006 June ** – Recovering from Chronic Disease: Sarcoidosis, Autoimmunity, AIDS, and Cancers conference held in Los Angeles. Notable speakers include Alan Cantwell MD.  **2006 June ** – Recovering from Chronic Disease: Sarcoidosis, Autoimmunity, AIDS, and Cancers conference held in Los Angeles. Notable speakers include Alan Cantwell MD. 
  
-**2006 July** – Marshall files for [[http://www.freepatentsonline.com/y2007/0149452.html|patent]] with US Patent and Trademark Office (eventually published in June 2007) which explains how an antibiotic-based therapy can treat and prevent AIDS and cancer.+**2006 July** – Marshall files for [[https://www.freepatentsonline.com/y2007/0149452.html|patent]] with US Patent and Trademark Office (eventually published in June 2007) which explains how an antibiotic-based therapy can treat and prevent AIDS and cancer.
  
 **2006 July** – Marshall presents poster at Days of Molecular Medicine, the first of three such annual presentations, which would alternate between Karolinska (Sweden) and Harvard. **2006 July** – Marshall presents poster at Days of Molecular Medicine, the first of three such annual presentations, which would alternate between Karolinska (Sweden) and Harvard.
Line 71: Line 71:
 **2007 July** – Marshall presents abstract at Metagenomics 2007, "[[home:publications:marshall_metagenomics_2007|Bacterial Capnine Blocks Transcription of Human Antimicrobial Peptides]]." The presentation provides proof of concept for the hypothesis that disease-causing bacteria can produce ligands which disable the Vitamin D Receptor. **2007 July** – Marshall presents abstract at Metagenomics 2007, "[[home:publications:marshall_metagenomics_2007|Bacterial Capnine Blocks Transcription of Human Antimicrobial Peptides]]." The presentation provides proof of concept for the hypothesis that disease-causing bacteria can produce ligands which disable the Vitamin D Receptor.
  
-**2008 February** – Marshall publishes in //Bioessays//, "[[home:publications:marshall_bioessays_2008|Vitamin D discovery outpaces FDA decision making]]."(({{pubmed>long:18200565}})) The paper explains how lifelong supplementation of the food chain with vitamin D might well be contributing to the current epidemics of obesity and chronic disease. It also puts forward the first working model of vitamin D metabolism.+**2008 February** – Marshall publishes in //Bioessays//, "[[home:publications:marshall_bioessays_2008|Vitamin D discovery outpaces FDA decision making]]."(({{pmid>long:18200565}})) The paper explains how lifelong supplementation of the food chain with vitamin D might well be contributing to the current epidemics of obesity and chronic disease. It also puts forward the first working model of vitamin D metabolism.
  
 **2008 September** – Marshall chairs session on vitamin D at International Congress on Autoimmunity in Porto, Portugal. Invited speakers for the session include Autoimmunity Research Foundation's [[home:publications:perez_congress_on_autoimmunity_2008|Capt. Tom Perez MPH]] and [[home:publications:marshall_congress_on_autoimmunity_2008|Marshall]]. Also speaking are MP physician [[home:publications:blaney_congress_on_autoimmunity_2008|Dr. Greg Blaney]] and MP colleague [[home:publications:proal_congress_on_autoimmunity_2008|Dr. Amy Proal]]. **2008 September** – Marshall chairs session on vitamin D at International Congress on Autoimmunity in Porto, Portugal. Invited speakers for the session include Autoimmunity Research Foundation's [[home:publications:perez_congress_on_autoimmunity_2008|Capt. Tom Perez MPH]] and [[home:publications:marshall_congress_on_autoimmunity_2008|Marshall]]. Also speaking are MP physician [[home:publications:blaney_congress_on_autoimmunity_2008|Dr. Greg Blaney]] and MP colleague [[home:publications:proal_congress_on_autoimmunity_2008|Dr. Amy Proal]].
Line 85: Line 85:
 {{tag> arf}} {{tag> arf}}
  
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
-broken links +//broken links// 
-"[[http://catalogue.library.uwa.edu.au/search/?searchtype=X&searcharg=marshall+and+Trevor&searchscope=5&SORT=AZ&extended=0&SUBMIT=Search&searchlimits=&searchorigarg=Xmarshall+and+Trevor%26SORT%3DA|Modelling and simulation in diabetes care]]+"[[https://catalogue.library.uwa.edu.au/search/?searchtype=X&searcharg=marshall+and+Trevor&searchscope=5&SORT=AZ&extended=0&SUBMIT=Search&searchlimits=&searchorigarg=Xmarshall+and+Trevor%26SORT%3DA|Modelling and simulation in diabetes care]]
  
-//[[http://www.sarcoidosis.it/home.html|Sarcoidosis, Vasculitis and Diffuse Lung Diseases]]//+//[[https://www.sarcoidosis.it/home.html|Sarcoidosis, Vasculitis and Diffuse Lung Diseases]]//
  
 +[[https://clinmed.netprints.org/cgi/content/full/2002080006|Valsartan Dosing Regime Modulates Psychotic Events in Two Sarcoidosis Patients]]
  
 +[[https://clinmed.netprints.org/cgi/content/full/2002080004|Remission in Sarcoidosis]]
 +[[https://sarcinfo.com|Sarcinfo.com]]
 +"[[https://clinmed.netprints.org/cgi/content/full/2002080004|Remission in Sarcoidosis]]" 
  
 +"[[https://clinmed.netprints.org/cgi/content/full/2003010001|New Treatments Emerge as Sarcoidosis Yields Up its Secrets]]" 
  
 +[[https://www.joimr.org/phorum/read.php?f=2&i=107&t=107|Antibacterial Therapy Induces Remission in Sarcoidosis]]
  
  
  
  
-===== References =====+ 
 + 
 +===== References =====</nodisp> 
home/arf/timeline.1550117794.txt.gz · Last modified: 02.14.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.